GSA Capital Partners LLP Takes $509,000 Position in Regeneron Pharmaceuticals, Inc. $REGN

GSA Capital Partners LLP bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 2nd quarter, HoldingsChannel reports. The institutional investor bought 817 shares of the biopharmaceutical company’s stock, valued at approximately $509,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. WPG Advisers LLC increased its holdings in Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares in the last quarter. SHP Wealth Management acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $26,000. Western Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $26,000. Titan Wealth CI Ltd bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $29,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $31,000. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on REGN shares. Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a “hold” rating in a research note on Wednesday, July 29th. Benchmark raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a research note on Tuesday, July 7th. Truist Financial raised their price target on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Wells Fargo & Company lifted their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a report on Monday, May 18th. Sixteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $801.70.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $834.04 on Friday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $541.00 and a 12-month high of $847.00. The business’s fifty day moving average is $697.09 and its 200 day moving average is $716.73. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The stock has a market cap of $85.87 billion, a P/E ratio of 20.61, a P/E/G ratio of 1.41 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. During the same quarter last year, the firm posted $12.81 EPS. Regeneron Pharmaceuticals’s revenue was up 16.7% compared to the same quarter last year. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the transaction, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $320,000.00. Following the sale, the director directly owned 603 shares of the company’s stock, valued at $482,400. This represents a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,400 shares of company stock valued at $1,090,030 over the last three months. Corporate insiders own 6.97% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Approval was supported by the Phase 3 OPTIMA trial, which showed a 90% or greater reduction in new lesions at 56 weeks. As the first approved treatment demonstrating this benefit in FOP, Pasatru could expand Regeneron’s rare-disease portfolio and create a new revenue stream. Regeneron to challenge Ipsen as FDA clears bone disease drug
• Positive Sentiment: Regeneron is also pursuing growth in obesity treatment. An update on its Phase 2 olatorepatide study has drawn investor attention because the program could give the company exposure to the large and rapidly expanding obesity-drug market, although clinical and commercial risks remain. Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside
• Neutral Sentiment: Multiple investor-law-firm notices announced a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to alleged disclosures about the Phase 3 Fianlimab-Libtayo melanoma trial; the notices themselves do not represent a new regulatory or operating development. Regeneron Investors Class Action Notice
• Negative Sentiment: The underlying litigation alleges that Regeneron misled investors about the viability and prospects of the Fianlimab-Libtayo trial, whose disappointing results reportedly caused a sharp share-price decline and an approximately $11 billion reduction in market value. Continued lawsuit announcements add reputational, legal-cost and potential financial-liability risks. Pomerantz Regeneron Investor Alert

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.